{"id":391,"date":"2018-10-19T00:17:22","date_gmt":"2018-10-19T00:17:22","guid":{"rendered":"http:\/\/www.ieee-nanomed.org\/2018\/?page_id=391"},"modified":"2018-10-19T00:20:13","modified_gmt":"2018-10-19T00:20:13","slug":"special-forum-on-nanomed-commercialization","status":"publish","type":"page","link":"http:\/\/www.ieee-nanomed.org\/2018\/program-details\/special-forum-on-nanomed-commercialization\/","title":{"rendered":"Special Forum on NANOMED Commercialization"},"content":{"rendered":"<p><span style=\"font-size: medium;\"><b><span style=\"margin: 0px; color: #454545; font-family: 'Arial',sans-serif;\">Overview.\u00a0 <\/span><\/b><span style=\"margin: 0px; color: #454545; font-family: 'Arial',sans-serif;\">In this past decade, NANOMEDICINE has been emerging from fundamental research to clinical translation and commercialization.\u00a0 To support this emerging trend in NANOMED, we introduce a special forum on NANOMED Commercialization to discuss issues related to\u00a0 commercialization of <img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-386 alignright\" style=\"background-color: transparent; box-sizing: border-box; color: #454545; display: block; float: right; font-family: &amp;quot; gudea&amp;quot;,tahoma,arial; font-size: 16px; font-style: normal; font-variant: normal; font-weight: bold; height: 135px; letter-spacing: normal; max-width: 765.2px; orphans: 2; outline-color: #72777c; outline-style: solid; outline-width: 1px; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; -webkit-text-stroke-width: 0px; white-space: normal; word-spacing: 0px; margin: 8px 0px 8px 24px;\" src=\"http:\/\/www.ieee-nanomed.org\/2018\/wp-content\/uploads\/2018\/10\/MichaelChen.jpg\" alt=\"\" width=\"142\" height=\"135\" \/>Nano\/Molecular Medicine and Engineering this year.\u00a0 <\/span><span style=\"margin: 0px; color: black; font-family: 'Arial',sans-serif;\">This forum will discuss procedures and strategies that can be used to facilitate the ongoing process of successful IP (especially patent) portfolio creation and management. These procedures include defining strategic patent goals that reflect the strategic corporate goals, maintaining an inventory of existing patents and related materials, and creating and implementing a procurement and management process in which decisions are made in light of the strategic goals.<\/span><\/span><\/p>\n<p><span style=\"font-size: medium;\"><b>Title. <\/b><b><i>Strategic IP Portfolio Management<\/i><\/b><\/span><\/p>\n<p><span style=\"font-size: medium;\"><b><span style=\"margin: 0px; color: black; font-family: 'Arial',sans-serif;\">Forum Speaker.<\/span><\/b><span style=\"margin: 0px; color: black; font-family: 'Arial',sans-serif;\">\u00a0 Michael Chen is a registered U.S. patent attorney specializing in protecting, developing and enforcing intellectual property assets domestically and internationally. He specializes in\u00a0intellectual property (patent, trademark, copyright) prosecution and litigation support, licensing transactions and IP portfolio management. With his strong and diverse technical background, Michael especially specializes in preparing and prosecuting patent applications in various technology fields including chemistry, nano\/biotechnology, microfluidics, semiconductor fabrication\/packaging, vehicle navigation device\/system, software, mechanical devices and novel human machine interfaces (HMI). He is also experienced in all areas of international IP prosecution, portfolio management and enforcement. Michael received his Juris Doctor (JD) degree from the University of Denver, Sturm College of Law in 2006. Before becoming an attorney, Michael was a research scientist in Genefluidics Inc., where he involved in the development of a hand-held DNA detection device with the application in clinical diagnostics. <\/span><\/span><\/p>\n<p><span style=\"margin: 0px; line-height: 107%; font-family: 'Arial',sans-serif; font-size: 12pt;\"><span style=\"color: #000000;\">\u00a0<\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Overview.\u00a0 In this past decade, NANOMEDICINE has been emerging from fundamental research to clinical translation and commercialization.\u00a0 To support this emerging trend in NANOMED, we introduce a special forum on NANOMED Commercialization to discuss issues related to\u00a0 commercialization of Nano\/Molecular Medicine and Engineering this year.\u00a0 This forum will discuss procedures<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":189,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-391","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"http:\/\/www.ieee-nanomed.org\/2018\/wp-json\/wp\/v2\/pages\/391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.ieee-nanomed.org\/2018\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/www.ieee-nanomed.org\/2018\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/www.ieee-nanomed.org\/2018\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.ieee-nanomed.org\/2018\/wp-json\/wp\/v2\/comments?post=391"}],"version-history":[{"count":2,"href":"http:\/\/www.ieee-nanomed.org\/2018\/wp-json\/wp\/v2\/pages\/391\/revisions"}],"predecessor-version":[{"id":394,"href":"http:\/\/www.ieee-nanomed.org\/2018\/wp-json\/wp\/v2\/pages\/391\/revisions\/394"}],"up":[{"embeddable":true,"href":"http:\/\/www.ieee-nanomed.org\/2018\/wp-json\/wp\/v2\/pages\/189"}],"wp:attachment":[{"href":"http:\/\/www.ieee-nanomed.org\/2018\/wp-json\/wp\/v2\/media?parent=391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}